Navigation Links
Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
Date:11/15/2010

l to provide local tumor control and improve quality of life. ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers including breast cancer. Localized mild hyperthermia (40-42 degrees Celsius) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

For primary liver cancer, ThermoDox® is being evaluated in a 600 patient global Phase III study at 76 clinical sites under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox® in combination with Radio Frequency Ablation (RFA) when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival and enrollment is anticipated to be completed in the first quarter of 2011. For recurrent chest wall breast cancer, ThermoDox® is being evaluated in a pivotal Phase I/II open-label, dose-escalating trial that is designed to measure durable local complete response at the tumor site. Celsion expects to fully enroll the Phase I portion of the study in the fourth quarter of 2010. Additional information on the Company's ThermoDox® clinical studies may be found at http://www.clinicaltrials.gov.

About CelsionCelsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System. Investor Conta
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
4. Par Pharmaceutical Reports Second Quarter 2008 Results
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. Pharmos Corporation Reports 2008 Second Quarter Results
7. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
9. BMP Sunstone Reports Second Quarter 2008 Financial Results
10. ULURU Inc. Reports Second Quarter 2008 Financial Results
11. Immtech Reports Fiscal First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Hydro Dynamics, Inc. (HDI) of Rome, ... will be partnering with Proteaf Technologies (Proteaf) of ... implementing its Shock Wave Power Reactor (SPR) cavitation ... flow chemistry through process intensification has been widely ... for decades. The continuous chemistry has been ...
(Date:9/13/2014)... PA (PRWEB) September 13, 2014 Boehringer ... device innovations, is proud to announce the successful broadcast ... Network bariatric surgeons Leonardo Claros, MD, FACS, FAMBS, and ... 3Dâ„¢ Sleeve Gastrectomy Calibration System. , This sleeve ... postgraduate course of more than four hundred surgeons from ...
(Date:9/12/2014)... 12, 2014 Research and Markets ... Film Photoresist Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth study ... photoresist industry . The report provides a ... and industry chain structure. The dry film photoresist market ...
(Date:9/11/2014)... MD (PRWEB) September 12, 2014 ... (LIMS), radio-frequency identification (RFID) solutions and sample management ... 5.1. , RURO completed work on the most ... August and it has already seen mass adoption, ... major release of version 5.0 brought an entirely ...
Breaking Biology Technology:Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Global Dry Film Photoresist Industry Report 2014 2Limfinity® Version 5.1 Available 2
... , DURHAM, N.C., Aug. 12 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... 10-K for the fiscal year ended April 30, 2009. In addition to being available ... v , the 10-K can be downloaded from the company website at ... the Investors page. , , For the year ended April 30, ...
... , , LYNBROOK, N.Y., Aug. 12 ... company developing first in class collagenase-based products, today announced its ... , , "We were very pleased ... with Priority Review for XIAFLEX(TM) for the treatment of Dupuytren,s ...
... , , SAN DIEGO, Aug. 12 ... results for the three and six months ended June 30, 2009. , ... have the capital to complete and submit a New Drug Application (NDA) ... said Brian M. Culley, Principal Executive Officer at ADVENTRX. "Our financial ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 2Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 2ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 3ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 4ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 5ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 7
(Date:9/15/2014)... week,s print issue of the journal Science ... New Mexico, Montana and even the Netherlands, thanks to ... more the norm in these connected times. Yes, the ... produce innovations in biology, medicine, biotechnology and agriculture. It ... talked with that one, that one knew another one, ...
(Date:9/15/2014)... leading coral reef ecologists fears that reef biodiversity may ... that we once thought. , In an international study ... of Excellence for Coral Reef Studies (Coral CoE) says ... species within reef ecosystems. , In coral reefs, just ... that keep the ecosystem safe and functioning. , ...
(Date:9/15/2014)... new strategic vision document, released today by the ... the long-term goals, objectives, and strategies for the ... over the next five years (2015-2020). In ... activities, to be funded in 2015, will include ... fellowships. , The $500 million, 30-year program ...
Breaking Biology News(10 mins):Collaboration drives achievement in protein structure research 2Specialized species critical for reefs 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... , , , , , , , ... , , , ... file available on request).,This noisy frog is a potent... , Click here for more ... , , , , , , ...
... with obese children shows that all diets are effective in ... one that accounts for how many carbs are in the ... glucose levels may be most promising. The Cincinnati ... and portion-controlled diets with obese children is published online in ...
... team has identified epigenetic signatures, markers on DNA that ... cells. These signatures can predict the expression of a ... stem cells (iPSCs), cells that take on embryonic stem ... is controlled brings us one step closer to developing ...
Cached Biology News:Common North American frog identified as carrier of deadly amphibian disease 2Common North American frog identified as carrier of deadly amphibian disease 3Common North American frog identified as carrier of deadly amphibian disease 4New study compares diets for weight management in obese children 2Epigenetic signatures direct the repair potential of reprogrammed cells 2
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse monoclonal antibody to RNase L...
Compact, portable device, seals 96 and 384 well plates with preset temperature optimised for Eppendorf heat sealing foils and films. Suitable for plates of different heights. AC input: 50/60 Hz230 V...
... Caliper is proud to work in ... Automation Certified 25mm syringe filters in a ... filters are licensed for use on the ... Detailed Specifications and Pricing for our Automation ...
Biology Products: